UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date ofearliest event reported): June 6,2016
CEN BIOTECH, INC.
(Exact nameof registrant as specified in its charter)
Ontario, Canada |
| 000-55557 |
|
|
(State or other jurisdiction of |
| (Commission File Number) |
| (I.R.S. Employer Identification |
incorporation) | Number) |
20 North Rear Road, Lakeshore, Ontario, CanadaN0R lK0
(Addressof principal executive offices)
Registrant's telephone number, including area code
226-344-0660
(Former name or formeraddress, if changed since last report)
Checktheappropriate box belowiftheForm8-Kfiling is intended to simultaneously satisfy the filing obligation oftheregistrant under any of the following provisions:
[ ] | Writtencommunications pursuant to Rule425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting materialpursuant to Rule 14a-12 underthe Exchange Act (17 CFR 240,l4a-12) |
[ ] | Pre-commencement communications pursuanttoRule 14d-2(b)under the Exchange Act (17CFR 240,14d-2(b)) |
[ ] | Pre-commencement communications pursuant toRule I 3e-4(c) under the Exchange Act ( I 7 CFR 240, 13e-4(c)) |
Unless otherwise indicated, in this Form 8-K, references to "we," "our," "us," the "Company," "CEN" or the "Registrant" refer to CEN Biotech, Inc.
Item 7.01 Regulation FD Disclosure.
On June 6, 2016, the Company issued a press release announcing the Company's discontinuance of the Application for Judicial Review ('AJR') filed in Canadian Federal Court., a copy of which is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated June 6, 2016 CEN Biotech Inc. Shareholder Update
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 8, 2016
CEN Biotech, Inc.
(Registrant)
/s/ Bill Chaaban
BILL CHAABAN
Chief Executive Officer